Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
This article was originally published in The Pink Sheet Daily
AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.
You may also be interested in...
AMAG’s Feraheme Expansion Strategy Delayed For Now
FDA has extended by three months its review of a sNDA for the I.V. iron product that would expand the drug’s use into a far broader patient population.
Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans
The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.
People In The News: Changes At EnVivo, CSL, Biomed, Orexo, NCPA, And More
Deborah Dunsire takes top leadership post at EnVivo and Paul Perreault at CSL Limited; Robert DeLuca to lead U.S. rollout of Orexo’s Zubsolv; Former CMS Deputy Director joins Avalere; more personnel announcements in this month’s column.